Top

Published in:

01-03-2018 | Research Letter

Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series

Published in: Endocrine | Issue 3/2018

Excerpt

As outlined in the latest recommendations for patients with type 2 diabetes (DM2), sodium glucose cotransporter 2 inhibitors (SGLT2i) can be added on treatments with metformin or sulfonylurea plus metformin if glycemic goals are not met [1]. Genital and urinary infections are well-known side effects of SGLT2i, with reported odds ratios in the range of 3.21–5.23, compared with placebo [2, 3]. …

W.T. Cefalu, M.C. Riddle, SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care 38(3), 352–354 (2015)CrossRef

D. Li, T. Wang, S. Shen, Z. Fang, Y. Dong, H. Tang, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. Epub ahead of print (2016)

W.T. Cefalu, L.A. Leiter, K.H. Yoon et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950 (2013)CrossRef

H. Yamasaki, K. Ogawa, H. Sasaki et al. Prevalence and risk factors of erectile dysfunction in Japanese men with type 2 diabetes. Diabetes Res. Clin. Pract. 66(Suppl 1), S173–S177 (2004)CrossRef

G.N. Collins, G.M. Raab, M. Hehir, B. King, W.M. Garraway, Observer variability and reproducibility of transrectal ultrasound in the measurement of prostatic volume. Ultrasound Med. Biol. 21, 1101 (1995)CrossRef

N. Kebapci, A. Yenilmez, B. Efe, E. Entok, C. Demirustu, Bladder dysfunction in type 2 diabetic patients. Neurourol. Urodyn. 26, 814–819 (2007)CrossRef

S. Geerlings, V. Fonseca, D. Castro-Diaz, J. List, S. Parikh, Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103, 373–381 (2014)CrossRef

C.C. Wang, M.B. Chancellor, J.M. Lin, J.H. Hsieh, H.J. Yu, Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int. 105, 1136–1140 (2010)CrossRef

H.J. Song, E.J. Lee, N. Bergstrom, D.H. Kang, D.H. Lee, G. Koh, J.S. Huh, S.D. Kim, S.C. Hong, S.S. Moon, J. Kang, Lower urinary tract symptoms and erectile dysfunction in men with type 2 diabetes mellitus. Int. Neurourol. J. 17, 180–185 (2013)CrossRef

10.

T. Heise, E. Seewaldt-Becker, S. Macha et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 15, 613–621 (2013)CrossRef

11.

S.O. Kim, H.S. Choi, Y.J. Kim et al. Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men. Int. Neurourol. J. 15, 82–86 (2011)CrossRef

12.

P.A. Low, L.M. Benrud-Larson, D.M. Sletten, T.L. Opfer-Gehrking, S.D. Weigand, P.C. O’Brien, G.A. Suarez, P.J. Dyck, Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 27, 2942–2947 (2004)CrossRef

13.

K. Rafiq, Y. Fujisawa, S.J. Sherajee, A. Rahman, A. Sufiun, H. Kobori, H. Koepsell, M. Mogi, M. Horiuchi, A. Nishiyama, Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58, 2885–2898 (2015)CrossRef

Title: Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
Publication date: 01-03-2018
Published in: Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1301-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test

Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender

New insights on diabetes in Turner syndrome: results from an observational study in adulthood

Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study

Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age

Treatment of benign thyroid nodules by high intensity focused ultrasound (HIFU) at different acoustic powers: a study on in-silico phantom

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page